BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Taştemur Ş, Ataseven H. Is it possible to use Proton Pump Inhibitors in COVID-19 treatment and prophylaxis? Med Hypotheses 2020;143:110018. [PMID: 32679422 DOI: 10.1016/j.mehy.2020.110018] [Cited by in Crossref: 8] [Cited by in F6Publishing: 10] [Article Influence: 4.0] [Reference Citation Analysis]
Number Citing Articles
1 Elekhnawy E, Negm WA, El-Sherbeni SA, Zayed A. Assessment of drugs administered in the Middle East as part of the COVID-19 management protocols. Inflammopharmacology 2022. [PMID: 36018432 DOI: 10.1007/s10787-022-01050-7] [Reference Citation Analysis]
2 Park J, You SC, Cho J, Park CH, Shin WG, Park RW, In Seo S. Comparative risk of incidence and clinical outcomes of COVID-19 among proton pump inhibitor and histamine-2 receptor antagonist short-term users: a nationwide retrospective cohort study. BMC Pharmacol Toxicol 2022;23:9. [PMID: 35039078 DOI: 10.1186/s40360-022-00549-7] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
3 da Rosa TF, Foletto VS, Serafin MB, Bottega A, Hörner R. Anti-infective properties of proton pump inhibitors: perspectives. Int Microbiol 2021. [PMID: 34476634 DOI: 10.1007/s10123-021-00203-y] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
4 Zippi M, Fiorino S, Budriesi R, Micucci M, Corazza I, Pica R, de Biase D, Gallo CG, Hong W. Paradoxical relationship between proton pump inhibitors and COVID-19: A systematic review and meta-analysis. World J Clin Cases 2021; 9(12): 2763-2777 [PMID: 33969059 DOI: 10.12998/wjcc.v9.i12.2763] [Cited by in CrossRef: 4] [Cited by in F6Publishing: 2] [Article Influence: 4.0] [Reference Citation Analysis]
5 Kariyawasam JC, Jayarajah U, Riza R, Abeysuriya V, Seneviratne SL. Gastrointestinal manifestations in COVID-19. Trans R Soc Trop Med Hyg 2021:trab042. [PMID: 33728439 DOI: 10.1093/trstmh/trab042] [Cited by in Crossref: 2] [Cited by in F6Publishing: 17] [Article Influence: 2.0] [Reference Citation Analysis]
6 Homolak J, Kodvanj I, Trkulja V. An Additional Perspective on Proton Pump Inhibitors as Risk Factors for COVID-19. Clin Drug Investig 2021;41:287-9. [PMID: 33606199 DOI: 10.1007/s40261-021-01007-8] [Reference Citation Analysis]
7 Zhang XY, Li T, Wu H, Ling Y, Qian ZP, Chen L. Analysis of the Effect of Proton-Pump Inhibitors on the Course of COVID-19. J Inflamm Res 2021;14:287-98. [PMID: 33574690 DOI: 10.2147/JIR.S292303] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
8 Rustgi V, Makar M, Minacapelli CD, Gupta K, Bhurwal A, Li Y, Catalano C, Panettieri R. In-Hospital Mortality and Prediction in an Urban U.S. Population With COVID-19. Cureus 2020;12:e11786. [PMID: 33409033 DOI: 10.7759/cureus.11786] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
9 Charpiat B, Bleyzac N, Tod M. Proton Pump Inhibitors are Risk Factors for Viral Infections: Even for COVID-19? Clin Drug Investig. 2020;40:897-899. [PMID: 32779119 DOI: 10.1007/s40261-020-00963-x] [Cited by in Crossref: 11] [Cited by in F6Publishing: 14] [Article Influence: 5.5] [Reference Citation Analysis]
10 Ray A, Sharma S, Sadasivam B. The Potential Therapeutic Role of Proton Pump Inhibitors in COVID-19: Hypotheses Based on Existing Evidences. Drug Res (Stuttg). 2020;70:484-488. [PMID: 32877948 DOI: 10.1055/a-1236-3041] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]